More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The self-expanding valve is not yet approved by the FDA, but care teams in other markets are reporting positive outcomes when patients go home the day after treatment.
That’s according to new PET imaging that shows the presence of activated T cells in the brain, spinal cord, gut and lung tissues of individuals who have recovered from COVID.
Between the ages of 8 and 12, MRI scans of children with ADHD show significantly lower cerebral blood flow in regions of the brain known to be related to attention, motor skills, executive function and impulsivity.
Electrophysiology specialist Vivek Reddy, MD, and colleagues reviewed data from more than 17,000 patients, presenting their findings in Nature Medicine.
The grant will fund a team at the UCLA Health Jonsson Comprehensive Cancer Center working to identify genetic biomarkers capable of predicting RT side effects.
A paper in the Journal of Vascular and Interventional Radiology offers new guidance on how ablation volumes affect renal function in solitary kidneys and highlights ranges that pose the least risk to patients.
